In the current study, we found that a strong B cell signature, defined by nCounter Human PanCancer Immune Profiling or CIBERSORT, was associated with CB in patients with ESCC treated with anti-PD-1-based or anti-D-L1-based immunotherapy. This evidence concerns the gene DLL1 and esophageal squamous cell carcinoma.